Françoise Meisch
A5063537382- Parkinson's Disease Mechanisms and Treatments
- DNA Repair Mechanisms
- Genomics and Chromatin Dynamics
- Gut microbiota and health
- Chromosomal and Genetic Variations
- RNA regulation and disease
- Advanced Causal Inference Techniques
- Cellular transport and secretion
- Neurological diseases and metabolism
- Nuclear Receptors and Signaling
- Folate and B Vitamins Research
- Autophagy in Disease and Therapy
- RNA Research and Splicing
- Biochemical and Molecular Research
- MicroRNA in disease regulation
- Lysosomal Storage Disorders Research
- Dysphagia Assessment and Management
- Carbohydrate Chemistry and Synthesis
- Diet and metabolism studies
- Neurological disorders and treatments
University of Luxembourg
2022-2024
Luxembourg Institute of Health
2024
Centre Hospitalier de Luxembourg
2024
Laboratoire National de Santé
2024
Institut Jacques Monod
2008-2011
Université Paris Cité
2008-2011
Sorbonne Université
2008
To get insights into the regulation of replication initiation, we systematically mapped origins along 1% human genome in HeLa cells. We identified 283 origins, 10 times more than previously known. Origin density is strongly correlated with genomic landscapes, clusters closely spaced GC-rich regions and no large GC-poor regions. sequences are evolutionarily conserved, half them map within or near CpG islands. Most overlap transcriptional regulatory elements, providing further evidence a...
Parkinson's disease (PD) is a systemic clinically defined by the degeneration of dopaminergic neurons in brain. While alterations gut microbiome composition have been reported PD, their functional consequences remain unclear. Herein, we addressed this question an analysis stool samples from Luxembourg Study (n = 147 typical PD cases, n 162 controls).All individuals underwent detailed clinical assessment, including neurological examinations and neuropsychological tests followed self-reporting...
Abstract Parkinson’s disease (PD) is a highly heterogeneous disorder influenced by several environmental and genetic factors. Effective disease-modifying therapies robust early-stage biomarkers are still lacking, an improved understanding of the molecular changes in PD could help to reveal new diagnostic markers pharmaceutical targets. Here, we report results from cohort-wide blood plasma metabolic profiling patients controls Luxembourg Study detect disease-associated alterations at level...
Abstract MicroRNAs act via targeted suppression of messenger RNA translation in the DNA–RNA–protein axis. The dysregulation microRNA(s) reflects epigenetic changes affecting cellular processes multiple disorders. To understand complex effect dysregulated microRNAs linked to neurodegeneration, we performed a cross-sectional microRNA expression analysis idiopathic Parkinson's disease (n = 367), progressive supranuclear palsy 35) and healthy controls 416) from Luxembourg Study, followed by...
Abstract Heterozygous variants in the glucocerebrosidase GBA1 gene are an increasingly recognized risk factor for Parkinson’s disease (PD). Due to GBAP1 pseudogene, which shares 96% sequence homology with coding region, accurate variant calling by array-based or short-read sequencing methods remains a major challenge understanding genetic landscape of -associated PD. We analyzed 660 patients PD, 100 Parkinsonism and 808 healthy controls from Luxembourg study, sequenced using amplicon-based...
Several phenotypic differences observed in Parkinson's disease (PD) patients have been linked to age at onset (AAO). We endeavoured find out whether these are due the ageing process itself by using a combined dataset of idiopathic PD (n = 430) and healthy controls (HC; n 556) excluding carriers known PD-linked genetic mutations both groups. found several significant effects AAO on motor non-motor symptoms PD, but when comparing with HC (using assessment, AAA), only positive associations AAA...
Abstract Introduction While there is an interest in defining longitudinal change people with chronic illness like Parkinson’s disease (PD), statistical analysis of data not straightforward for clinical researchers. Here, we aim to demonstrate how the choice method may influence research outcomes, (e.g., progression apathy), specifically size effect estimates, a cohort. Methods In this retrospective 802 typical Luxembourg Parkinson's study, compared mean apathy scores at visit 1 and 8 by...
Abstract Gut microbiome differences between people with Parkinson’s disease (PD) and control subjects without Parkinsonism are widely reported, but potential alterations related to PD mild cognitive impairment (MCI) have yet be comprehensively explored. We compared gut microbial features of MCI ( n = 58) cognitively unimpaired 60) 90) normal cognition. Our results did not support a specific signature in PD.
Abstract Background Parkinson's disease (PD), while often associated with its distinctive motor symptoms, can also exert a notable impact on the cardiovascular system due to development of severe autonomic dysfunction. One initial indicators PD is appearance dysautonomia. As such, it vital monitor and manage health individuals PD, as may have clinical implications in commonly recognized non-motor aspects disease. To study association history (CVD) occurrence severity here, we lend data CVD...